GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » 3-Year EPS without NRI Growth Rate

Hikma Pharmaceuticals (LSE:HIK) 3-Year EPS without NRI Growth Rate : 11.00% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Hikma Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2023 was £0.74.

During the past 12 months, Hikma Pharmaceuticals's average EPS without NRI Growth Rate was 18.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was 11.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 7.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Hikma Pharmaceuticals was 59.40% per year. The lowest was -6.50% per year. And the median was 12.20% per year.


Competitive Comparison of Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Hikma Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hikma Pharmaceuticals  (LSE:HIK) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hikma Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hikma Pharmaceuticals (LSE:HIK) Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines